Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

any will continue advancing its highest priority programs (see "Research and Development Expenses") while operating within an annual burn rate of approximately $9 million to $10 million (reduced from previously expected range of $11 million to $13 million principally due to delaying some non-essential development activities). The magnitude of spending in the Company's development programs will be dependent on the licensing status of the celgosivir program and results in the various programs. We may need to increase or decrease our annual burn rate in response to such results. MIGENIX is likely to need to raise additional funds in support of its operations and there is no assurance that such funds can be obtained.

Outstanding Shares

There are currently 94,463,806 (January 31, 2008: 94,463,806; April 30, 2007: 94,237,205) common shares outstanding; 29,465 convertible royalty participation units (January 31, 2008 and April 30, 2007: 29,465); and 5,250,000 (January 31, 2008: 5,250,000; April 30, 2007: 9,350,000) preferred shares outstanding. During Q3/08 we redeemed 4,000,000 Series E preferred shares for the aggregate sum of US$1 as the milestone obligations associated with these shares expired August 31, 2007.

----------------------------------------------------------------------- --

Conference Call

Investors, analysts and the media are invited to participate in a conference call and webcast on Thursday, March 13 at 11:00 a.m. ET (8:00 a.m. PT) to discuss this announcement. An update on company activities will also be provided. To participate in the conference call, please dial 416-644-3417 or 1-800-732-0232. The call will be available for replay until March 27, 2008 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21263848 followed by the number sign. The live and archived webcast will be accessible through the company's website at http://www.migenix.com for the
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
(Date:5/17/2013)... 17, 2013  Insero Health, Inc., a company developing ... and related neurological disorders, is today reporting top-line results ... INS001 in patients with drug-resistant epilepsy.  The data are ... (AED) Xll meeting by Dr. Steven Schachter ... Insero,s Scientific Advisory Board.  In this study, INS001 appeared ...
(Date:5/17/2013)... Frederick, MD (PRWEB) May 17, 2013 ... release of ezColony version 4.1, a versatile refinement ... world-class premier software solution, improves its advanced methodical ... animal facilities with ezColony 4.1. The network-based platform ... to conduct effective research. While continuing to emphasize ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Tooth decay is ... showing active signs of the disease. The World Health Organization ... nearly 100% of adults have cavities. What are the long-term ... is showing a strong connection between the oral bacterial imbalance ... this disease so rampant, yet it is also 100% preventable? ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... dr. Stuart Parkin as its first ,distinguished professor, ever. Parkin ... of the IBM Almaden Research Center in the USA. Earlier ... Parkin is an expert in the field of spintronics. , ... international top professor to be appointed to this position for ...
... IDIX ) announced today that it will report,its ... Thursday, October,30, 2008 after the U.S. financial markets close., ... release, Idenix,management will host a conference call at 4:30 ... company,s financial results for the third quarter,of 2008 and ...
... Our Children Foundation,a nonprofit charitable foundation dedicated to ... Administration (FDA) has approved the Orphan,Drug Designation of ... Sarcoma cancer. The efforts to develop this drug ... in private industry and at two,universities., Orphan ...
Cached Biology Technology:FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children 2
(Date:5/17/2013)... iCargo project (Intelligent Cargo in Efficient and Sustainable Global ... to an improvement in the efficiency of intermodal loading ... decision making. It comprises 29 European organisations with experience ... It has a budget totalling 17,000,000 and a duration ... working to specify and develop the semantic components and ...
(Date:5/17/2013)... Bethesda, MD The Federation of American Societies for ... of National Institutes of Health (NIH) funding trends highlighting ... to support critical research. The FASEB analysis follows a ... Francis Collins, MD, PhD, who testified that the $1.6 ... to sequestration is "having a substantial impact on the ...
(Date:5/16/2013)... Illustrating a commitment to the support of ... (AGA) Research Foundation has announced the inaugural AGA ... recipients. Supported by the National Institute of Diabetes ... award helps underrepresented minority students to further their ... , "By establishing this new award, AGA demonstrates ...
Breaking Biology News(10 mins):New logistics services that will cut energy consumption and CO2 emissions 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
... tell no tales has long been disproved by archaeology. ... to new heights. In a study that promises fresh and ... New World, a team or researchers from the University of ... the teeth of crew members Christopher Columbus left on the ...
... is gone -- not just over the poles, but everywhere. ... 1980s, is a year-round fixture, with a twin over the ... like Washington, D.C., is strong enough to cause sunburn in ... with likely harmful effects on plants, animals and human skin ...
... insecticide commonly used up until the 1970s may play a ... new study involving several Michigan State University researchers. More ... Lake Michigan were studied for their exposure to DDE ... choice in this month,s edition of Occupational and Environmental ...
Cached Biology News:Teeth of Columbus' crew flesh out tale of new world discovery 2Teeth of Columbus' crew flesh out tale of new world discovery 3New simulation shows consequences of a world without Earth's natural sunscreen 2New simulation shows consequences of a world without Earth's natural sunscreen 3New simulation shows consequences of a world without Earth's natural sunscreen 4Exposure to insecticide may play role in obesity epidemic among some women 2
Mouse/Rat WNK1 Affinity Purified Polyclonal Ab...
... of excess dye terminators, template DNA, primers, ... true sequencing products have proved critical for ... is designed to work with dye terminator ... DYEnamicTM ET. The unique uniformity of the ...
Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
uncoupling protein 2 (mitochondrial, proton carrier), mRNA (cDNA clone MGC:19567 IMAGE:4335185), complete cds...
Biology Products: